Abasaglar - 100 IU/ml

Injection

Pack Size : 1 Pen x 1 Packet

Generics : Insulin Glargine

Manufacturer : Healthcare Pharmaceuticals Ltd.

Best Price * TK 1,085.00

* Delivery will be done in Dhaka city only.

Alternative Product

Injection Lantus 100U/ML CARTRIDGES Sanofi Aventis (BD) Ltd.

Tk 785.00

Injection Vibrenta 100 IU/ml Soln For Inj Incepta Pharmaceuticals Ltd.

Tk 600.00

Injection Glarine - 100IU/ml ACI Limited

Tk 600.00

Injection Larsulin 100 IU/3 ml Penset - 100 IU/ml Square Pharmaceuticals Ltd.

Tk 600.00

Insulin Abasaglar - 3ml Cartige Healthcare Pharmaceuticals Ltd.

Tk 723.40

More Information About - Abasaglar - 100 IU/ml

Description

Generic Name

Insulin Glargine

Precaution

Renal or hepatic impairment; pregnancy; lactation; child <6 yrs. Transferring from other insulin. Monitor serum glucose, potassium, electrolytes, HbA1c and lipid profile. Concomitant illness esp infections; hypokalaemia. Lactation: Considered safe for use while breast feeding

Indication

Diabetes mellitus

Contra Indication

Hypoglycaemia; IV route.

Dose

N/A

Side Effect

Hypoglycaemia, lipodystrophy, pruritus, rash, wt gain, sodium retention and oedema. Inj site reactions e.g. pain, itching, hives, swelling and inflammation. Influenza-like symptoms, Pallor, Palpitation, Tachycardia, Mental confusion, Weakness, Blurred vision, Itching, Hunger, Nausea.

Pregnancy Category

Name : Not Classified

Description

FDA has not yet classified the drug into a specified pregnancy category.

Mode of Action

Insulin glargine, a long-acting analog of human insulin, regulates carbohydrate, protein and fat metabolism by inhibiting hepatic glucose production and lipolysis, and enhancing peripheral glucose disposal.

Interaction

Effects may be increased by: oral antidiabetic agents, ACE inhibitors, disopyramide, fibrates, fluoxetine, MAOIs, propoxyphene, salicylates, somatostatin analog (e.g. octreotide), sulfonamide antibiotics. Effects may be decreased by: corticosteroids, niacin, danazol, diuretics, sympathomimetic agents, isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, oral contraceptives, lithium. Signs of hypoglycaemia may be masked by beta-blockers, clonidine.

Pregnancy Category Note

Pregnancy Published data do not report a clear association with insulin glargine products and major birth defects, miscarriage, or adverse maternal or fetal outcomes when insulin glargine products used during pregnancy; however, these studies cannot definitely establish absence of any risk because of methodological limitations including small sample size and some with no comparative group There are risks to mother and fetus associated with poorly controlled diabetes in pregnancy; poorly controlled diabetes in pregnancy increases maternal risk for diabetic ketoacidosis, pre-eclampsia, spontaneous abortions, preterm delivery, stillbirth and delivery complications Animal data In animal reproduction studies, rats and rabbits were exposed to insulin glargine in animal reproduction studies during organogenesis, respectively 50 times and 10 times the human subcutaneous dose of 0.2 units/kg/day; overall, effects of insulin glargine did not generally differ from those observed with regular human insulin Lactation There are no data on presence of insulin glargine in human milk, effects on breastfed infant, or on milk production Use of insulin glargine is compatible with breastfeeding, but women with diabetes who are lactating may require adjustments of their insulin doses; health benefits of breastfeeding should be considered along with mother?s clinical need for therapy and any potential adverse effects on breastfed child from drug or from underlying maternal condition

Adult Dose

Subcutaneous Type 1 or 2 Diabetes Mellitus Initial dose Type 1 diabetes mellitus: Starting dose should be approximately one third of the total daily insulin requirements; short-acting, premeal insulin should be used to satisfy the remaining two thirds of the daily insulin requirements; insulin glargine should be used in combination with a short-acting or rapid-acting insulin; Type 2 diabetes mellitus: Starting dose in patients who are not currently treated with insulin is 10 units (or 0.2 unit/kg) once daily Dosage should be individualized in accordance with the needs of the patient and adjusted according to blood glucose measurement Converting from other insulins If changing from a treatment regimen with an intermediate- or long-acting insulin to a regimen with insulin glargine, the amount and timing of shorter-acting insulins and doses of any oral antidiabetic drugs may need to be adjusted From once-daily NPH insulin to once-daily insulin glargine: Initial dose is the same as the dose of NPH that is being discontinued From twice-daily NPH insulin to once-daily insulin glargine: Initial dose is 80% of the total daily NPH dose that is being discontinued; this dose reduction will lower the likelihood of hypoglycemia Dosing Considerations Indicated for once-daily SC administration; exhibits relatively constant glucose-lowering profile over 24 hr May be administered at any time during the day; should be administered SC once daily at the same time every day Dose must be individualized based on clinical response; blood glucose monitoring is essential in all patients receiving insulin therapy In patients with type 1 diabetes, insulin glargine must be used in regimens with short-acting insulin As with all insulins, injection sites should be rotated within the same region (abdomen, thigh, or deltoid) from one injection to the next to reduce the risk of lipodystrophy; no clinically relevant difference in insulin glargine absorption after abdominal, deltoid, or thigh SC administration As with all insulins, the rate of absorption and, consequently, the onset and duration of action may be affected by exercise and other variables (eg, stress, intercurrent illness, changes in coadministered drugs, meal patterns)

Child Dose

Type 1 Diabetes Mellitus It is a long-acting human insulin analogue indicated to improve glycemic control in children with type 1 diabetes mellitus; <6 years: Safety and efficacy not established >6 years: Approximately one third of the total daily insulin requirements SC; rapid-acting or short-acting, premeal insulin should be used to satisfy the remaining two thirds of the daily insulin requirements; usual daily maintenance range in adolescents is <1.2 units/kg/day during growth spurts

Renal Dose

Renal impairment: Dose adjustments may be needed.

Administration

Administer subcutaneously in the upper arm, thigh or abdominal wall. A subcutaneous injection into the abdominal wall results in a faster absorption than from other injection sites. Should not be administered IV or via an insulin pump; IV administration of the usual SC dose could result in severe hypoglycemia

Disclaimer

The information provided herein are for informational purposes only and not intended to be a substitute for professional medical advice, diagnosis, or treatment. Please note that this information should not be treated as a replacement for physical medical consultation or advice. Great effort has been placed to provide accurate and comprehensive data. However, Medicart along with its authors and editors make no representations or warranties and specifically disclaim all liability for any medical information provided on the site. The absence of any information and/or warning to any drug shall not be considered and assumed as an implied assurance of the Company.